Pharmaceuticals, Biotechnology and Life Sciences
Schreiner MediPharm developed the Patch-Safe specialty label for PS Marketing & Outsourcing GmbH, to be used for safe disposal of patches containing active ingredients.
Transgene confirms that the study’s primary
endpoint (objective response rate – ORR) on a minimum of 35 evaluable
patients will be reported in Q4 2019.
Veratrak, a UK-based software provider dedicated to transforming supply chains across the life science industry, said Wednesday in a press release that contract packaging organisation (CPO) Central Pharma has selected its platform to help it achieve digitised end-to-end visibility of its supply chain and improve collaboration.
Synlogic in clinical collaboration with Roche to explore Synlogic’s Synthetic Biotic medicine for advanced solid tumors
Debiopharm has enrolled first patient in SMARTPLUS-106, a Phase lb/II study in patients failing prior PD-1/PD-L1 treatment in selected solid tumors.
The development of the UK’s first dedicated Vaccines Manufacturing Innovation Centre (VMIC) has moved a step closer with the contract to design an advanced array of laboratory and production facilities within a ‘cleanroom wrap’ environment being awarded to WHP, the company has said in a statement.
The KEYTRUDA breast cancer clinical development program encompassesseveral internal and external collaborative studies, including threeongoing registration-enabling studies in TNBC.
Verona Pharma posted Monday expanded analysis to positive results from March, from from findings from its chronic obstructive pulmonary disease (“COPD”) clinical trial program with lead product candidate, ensifentrine (RPL554). Positive results from the 4-week, 400-patient Phase 2b study were initially reported in March 2018.
The global pulmonary embolism therapeutics market is expected to post aCAGR of more than 9% during the period 2019-2023, according to thelatest market research report by Technavio.
DUBLIN–(BUSINESS WIRE)–The “Atopic Dermatitis: Global Drug Forecast and Market Analysis to 2027” report has been added to ResearchAndMarkets.com’s offering. The…